BioSpace News Archive

The research report on global syphilis testing market sheds light on various core trends and drivers that are expected to fast track the growth of the industry in coming years.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Infants or neonatal are generally susceptible to a lot of diseases.

Nuvalent, Inc. announced it will present two posters for its parallel lead programs, NVL-655, an ALK-selective inhibitor and NVL-520, a ROS1-selective inhibitor, at the IASLC 2022 World Conference on Lung Cancer Annual Meeting taking place August 6-9, 2022 in Vienna, Austria.

Dr. Sergey Motov at Maimonides Medical Center to Host Webinar on using MeMed BV® in the Emergency Department to rapidly differentiate bacterial and viral infections.

XORTX Therapeutics Inc. is pleased to announce positive topline results from Part 1 of the three part Pharmacokinetics Bridging Study – XRX-OXY-101 (“PK Clinical Trial”) - showing a substantial increase in oral bioavailability of two versions of XORTX’s proprietary oxypurinol formulation compared to a control formulation.

Quest Diagnostics today announced the nationwide availability* of the company’s lab-developed molecular diagnostic test to aid in the diagnosis of infection with the monkeypox virus, with plans to launch the CDC’s orthopoxvirus test in the first half of August.

Purity- IQ is pleased to announce that esteemed scientist Dr. Henry J. Stronks FCIC has joined the organization’s executive team as Chief Science Officer.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference on Wednesday, July 20, 2022.

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII) will release fourth-quarter results the evening of August 2. In lieu of hosting a quarterly earnings conference call, CSI management will discuss fourth-quarter results at the beginning of its capital markets day on August 3.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2022 financial results after the market close on Wednesday, August 3, 2022.